Spots Global Cancer Trial Database for dose expansion
Every month we try and update this database with for dose expansion cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Phase I Study of RGT-264 in Subjects With Advanced Solid Tumors | NCT05764915 | Advanced Solid ... | RGT-264 phospha... | 18 Years - 80 Years | Regor Pharmaceuticals Inc. | |
| First-time-in-human (FTIH) Study of GSK3145095 Alone and in Combination With Other Anticancer Agents in Adults With Advanced Solid Tumors | NCT03681951 | Neoplasms, Panc... | GSK3145095 Pembrolizumab | 18 Years - | GlaxoSmithKline | |
| Alisertib (MLN8237) in Combination With Weekly Paclitaxel in East Asian Patients With Advanced Solid Tumors | NCT02367352 | Advanced Solid ... Ovarian Cancer Small Cell Lung... | Alisertib Paclitaxel | 18 Years - | Takeda | |
| An Investigation of TAS-119 Monotherapy | NCT02448589 | Advanced Solid ... | TAS-119 | 18 Years - | Taiho Oncology, Inc. | |
| Clinical Phase I Study Investigating MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Advanced Solid Tumors or Chronic Lymphocytic Leukemia | NCT02316197 | Advanced Solid ... Chronic Lymphoc... | MSC2490484A (M3... | 18 Years - | Merck KGaA, Darmstadt, Germany | |
| Phase I Trial of BAY1251152 for Advanced Blood Cancers | NCT02745743 | Hematologic Neo... | BAY1251152 | 18 Years - | Bayer | |
| A Study of NOX66 and External Beam Radiotherapy in Patients With Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors | NCT04957290 | Metastatic Cast... | NOX66 NOX66 NOX66 NOX66 NOX66 EBRT | 18 Years - | Noxopharm Limited | |
| Phase I Trial of BAY1251152 for Advanced Blood Cancers | NCT02745743 | Hematologic Neo... | BAY1251152 | 18 Years - | Bayer | |
| PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma | NCT03460977 | Castration Resi... Small Cell Lung... Follicular Lymp... | PF-06821497 | 18 Years - | Pfizer | |
| First-time-in-human (FTIH) Study of GSK3145095 Alone and in Combination With Other Anticancer Agents in Adults With Advanced Solid Tumors | NCT03681951 | Neoplasms, Panc... | GSK3145095 Pembrolizumab | 18 Years - | GlaxoSmithKline | |
| JTX-2011 Alone and in Combination With Anti-PD-1 or Anti-CTLA-4 in Subjects With Advanced and/or Refractory Solid Tumors | NCT02904226 | Cancer | JTX-2011 Nivolumab Ipilimumab Pembrolizumab | 18 Years - | Jounce Therapeutics, Inc. | |
| PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors | NCT03685591 | Breast Neoplasm... Prostate Neopla... Neoplasms, Squa... Melanoma Mesothelioma Pancreatic Neop... Colorectal Neop... Carcinoma, Rena... Liver Neoplasms | PF-06952229 Enzalutamide | 18 Years - | Pfizer | |
| A Study of NPX887 for Participants With Solid Tumors Known to Express HHLA2/B7-H7 | NCT06240728 | Metastatic Mali... | NPX887 | 18 Years - | NextPoint Therapeutics, Inc. | |
| First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas | NCT03188965 | Advanced Solid ... Non-Hodgkin's L... Mantle Cell Lym... | Elimusertib (BA... | 18 Years - | Bayer | |
| Study of AGEN1571 in Participants With Advanced Solid Tumors | NCT05377528 | Advanced Solid ... | AGEN1571 Balstilimab Botensilimab | 18 Years - | Agenus Inc. | |
| A Study of NOX66 and External Beam Radiotherapy in Patients With Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors | NCT04957290 | Metastatic Cast... | NOX66 NOX66 NOX66 NOX66 NOX66 EBRT | 18 Years - | Noxopharm Limited | |
| An Investigation of TAS-119 Monotherapy | NCT02448589 | Advanced Solid ... | TAS-119 | 18 Years - | Taiho Oncology, Inc. | |
| A Phase 1 Dose Escalation Study of AMG 780 in Adult Subjects With Advanced Solid Tumors | NCT01137552 | Advanced Solid ... | AMG 780 | 18 Years - | Amgen | |
| An Investigation of TAS-119 Monotherapy | NCT02448589 | Advanced Solid ... | TAS-119 | 18 Years - | Taiho Oncology, Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
